MTOR and fragile X syndrome: First, FXS is characterized by an uncontrolled activity of the metabotropic glutamate receptor 5 [15,16] and abnormal mammalian target of rapamycin (mTOR) signaling [17,18,19], two pathways that are heavily involved in ECS functionality [20,21,22,23].